apoioI

data

Agenda

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

ORAL ABSTRACT SESSION | Abstract 3501 | Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

Presenter: Michael J. Overman, MD

Informação Adicional

  • Data de Início domingo, 05 junho 2016
  • Data de Fim domingo, 05 junho 2016
  • Horário 8:12- 8:24
  • Localidade Location: Hall B1

ASCO/European cancer organization (ECCO) joint session: value-based care

Chair(s): Peter L. J. Naredi, MD, PhD, Sahlgrenska University Hospital, University of Gothenburg; Julie Vose, MD, MBA, FASCO, University of Nebraska Medical Center

Introduction to Value-Based Care

9:45- 10:00

Barbro Friden, MD, PhD

Value-Based Care in Prostate Cancer: European Perspective

10:00 - 10:10

Hans Heinzer, MD, PhD

Value-Based Care in Prostate Cancer: U.S. Perspective

10:10 - 10:20

Maha Hussain, MD, FACP, FASCO

Value-Based Care in Colorectal Cancer: European Perspective

10:30 - 10:40

Rob A.E.M. Tollenaar, MD, PhD

Value-Based Care in Colorectal Cancer: U.S. Perspective

10:40 - 10:50

Wells A. Messersmith, MD - Speaker

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 09:45- 11:00
  • Localidade S100bc

Access to cancer therapeutics in low-and middle-income countries

Chair: Paul Ruff, MBBCH, MMed, FCP(SA), University of Witwatersrand Faculty of Health Sciences

Drug Access and Approval in Low-Income Countries.

11:30 - 11:50

Sana A. Al Sukhun, MD, MSc

WHO List of Essential Medicines and Devices: Maximizing Cancer Care Value

11:50 - 12:10

Lawrence N. Shulman, MD

Cultural and Regulatory Barriers to Treating Cancer Pain.

12:10 - 12:30

Paul Ruff, MBBCH, MMed, FCP(SA)

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 11:30-12:45
  • Localidade S102

Economic and regulatory Implications in drug development for sarcoma and rare cancers: the identification of value and quality.

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 16:45 - 18:00
  • Localidade S404

Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy

for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.

CLINICAL SCIENCE SYMPOSIUM | Abstract 6009 | Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.

Presenter: Robert L. Ferris, MD, PhD

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 11:30 - 11:42
  • Localidade S100bc

Quality of life (QoL) and overall survival (OS) in patients (pts)

with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.

POSTER SESSION | Abstract  4549  | Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study. Poster Board: #171

Presenter: David Cella, PhD

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 13:00 - 16:30
  • Localidade Hall A

Updated results from a phase III trial of nivolumab (NIVO)

combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Arie Crown Theater

ORAL ABSTRACT SESSION | Abstract  9505  | Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Presenter:  Jedd D. Wolchok, MD, PhD

Informação Adicional

  • Data de Início segunda, 06 junho 2016
  • Data de Fim segunda, 06 junho 2016
  • Horário 14:39 - 14:51

Biosimilars: here and now

Chair: Steven J. Lemery, MD,MHS, U.S. Food and Drug Administration

Informação Adicional

  • Data de Início terça, 07 junho 2016
  • Data de Fim terça, 07 junho 2016
  • Horário 08:00- 9:15
  • Localidade E450ab

Store News Farma

Newsletter

Área Reservada

Os portugueses na ASCO 2016

Dr.ª Ana Castro

Dr. José Duro da Costa

Dr.ª Fátima Cardoso

Dr.ª Lourdes Barradas

Dr.ª Maria Teresa

Prof. Doutor Venceslau Hespanhol

Dr. Sérgio Barroso

Dr. Hélder Mansinho

Prof. Doutor António Araújo

Dr.ª Gabriela Sousa

Dr.ª Mónica Nave

Dr.ª Teresa Timoteo

Prof. Doutor José Passos Coelho